Nasdaq IPOs

Genetron Holdings, which uses molecular profiling to provide diagnostic services for cancer patients in China, announced terms for its IPO on Monday. The Beijing, China-based company plans to raise $163 million by offering 13 million ADSs at a price range of $11.50 to $13.50. Ins

Progenity, which sells in vitro molecular tests for prenatal and disease screening, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14 to $16. Insiders intend to purchase $50 mi

Progenity, which sells in vitro molecular tests for prenatal and disease screening, announced terms for its IPO on Monday. The San Diego, CA-based company plans to raise $100 million by offering 6.7 million shares at a price range of $14 to $16. Insiders intend to purchase $50 mi

Repare Therapeutics, a preclinical biotech developing gene therapies for solid tumors, announced terms for its IPO on Monday. The Cambridge, MA-based company plans to raise $125 million by offering 7.4 million shares at a price range of $16 to $18. At the midpoint of the proposed

Forma Therapeutics, a Phase 1 biotech company developing therapies for hematologic diseases and cancers, announced terms for its IPO on Monday. The Watertown, MA-based company plans to raise $200 million by offering 11.8 million shares at a price range of $16 to $18. At the midpo

Updated Monday, 6/15. Following back-to-back eight-IPO weeks, the IPO market's summer surge continues with five IPOs scheduled for the week ahead. As expected, several companies launched on Monday with pricing set for later in the week. Pharmaceutical royalty acquirer Royalty Pha

Updated Monday, 6/15. Following back-to-back eight-IPO weeks, the IPO market's summer surge continues with five IPOs scheduled for the week ahead. As expected, several companies launched on Monday with pricing set for later in the week. Pharmaceutical royalty acquirer Royalty Pha

Updated Monday, 6/15. Following back-to-back eight-IPO weeks, the IPO market is taking a breather with four IPOs scheduled for the week ahead. That said, several companies could launch on Monday to price later in the week. Pharmaceutical royalty acquirer Royalty Pharma (RPRX) pla

Following back-to-back eight-IPO weeks, the IPO market is taking a breather with just one IPO scheduled for the week ahead. That said, several companies could launch on Monday to price later in the week. Pharmaceutical royalty acquirer Royalty Pharma (RPRX) plans to raise $1.9 bi

Following back-to-back eight-IPO weeks, the IPO market is taking a breather with just one IPO scheduled for the week ahead. That said, several companies could launch on Monday to price later in the week. Pharmaceutical royalty acquirer Royalty Pharma (RPRX) plans to raise $1.9 bi

Eight IPOs and one SPAC entered the public markets this past week led by Vroom (VRM), which popped 118% in the best first day for a tech IPO since 2018. Three health care IPOs finished the week up more than 40%. Every IPO this quarter has either upsized its offering or priced abo

PTK Acquisition, a blank check company targeting a technology business, filed on Friday with the SEC to raise up to $100 million in an initial public offering. The Los Angeles, CA-based company plans to raise $100 million by offering 10 million units at a price of $10. Each unit

Panacea Acquisition, a blank check company formed by EcoR1 Capital targeting the biotech industry, filed on Friday with the SEC to raise up to $125 million in an initial public offering. The company plans to raise an additional $25 million through a forward purchase agreement wit

NuZee, which packages and sells single-serve coffee products, increased the proposed share offering for its upcoming IPO on Friday. The Plano, TX-based company now plans to raise $6 million by offering 0.7 million shares at $9, the May 20th close of its shares on the OTCQB (NUZE)

Car House Holding, which operates an online B2B marketplace for car products in China, filed on Friday with the SEC to raise up to $37 million in an initial public offering. The company began its business in developing, manufacturing, and selling auto perfume and air fresheners.

Burning Rock Biotech, which provides DNA sequencing-based cancer therapy selection tests in China, raised $223 million by offering 13.5 million ADSs at $16.50, above the range of $13.50 to $15.50. Insiders had indicated on $79 million of the IPO (35% of the deal). The company rai

Vaxcyte, a preclinical biotech developing next-generation pneumococcal vaccines, raised $250 million by offering 15.6 million shares at $16, the high end of the range of $14 to $16. The company offered 1.6 million more shares than anticipated. At pricing, the company commands a f

Avidity Biosciences, a preclinical biotech developing antibody therapies for muscle disorders, raised $259 million by offering 14.4 million shares at $18, the high end of the upwardly revised range of $17 to $18. Earlier on Thursday, the La Jolla, CA-based company raised the

The AZEK Company, which manufactures composite decking materials and other building products, raised $765 million by offering 33.3 million shares at $23, above the range of $19 to $21. The company sold 2.0 million shares more than anticipated. At pricing, AZEK commands a fully di

The AZEK Company, which manufactures composite decking materials and other building products, raised $765 million by offering 33.3 million shares at $23, above the range of $19 to $21, as indicated by an S-1MEF form filed with the SEC. The company sold 2.0 million shares mor